AbbVie prices Rinvoq close to Humira after arthritis approvalAbbVie claimed FDA approval for its JAK inhibitor Rinvoq (upadacitinib) for rheumatoid arthritis on Friday, setting its price Share XAbbVie prices Rinvoq close to Humira after arthritis approvalhttps://pharmaphorum.com/news/abbvie-prices-upadacitinib-close-to-humira-after-arthritis-approval/
Allergan says it will shed two drugs as AbbVie takeover loomsAllergan has confirmed that it will divest experimental inflammatory bowel disease therapy brazikumab and marketed drug Zenpep ahead Share XAllergan says it will shed two drugs as AbbVie takeover loomshttps://pharmaphorum.com/news/allergan-says-it-will-shed-two-drugs-as-abbvie-takeover-looms/
Roche under pressure in US as Amgen/Allergan launch US cancer biosimilarsAmgen and Allergan have launched their cut-price biosimilar competitors to two big-selling cancer drugs from Roche in the Share XRoche under pressure in US as Amgen/Allergan launch US cancer biosimilarshttps://pharmaphorum.com/news/roche-under-pressure-in-us-as-amgen-allergan-launch-us-cancer-biosimilars/
NICE recommends funding for psoriasis and type 1 diabetes drugsPatients in England and Wales should soon be able to access AbbVie’s psoriasis drug Skyrizi after NICE recommended Share XNICE recommends funding for psoriasis and type 1 diabetes drugshttps://pharmaphorum.com/news/nice-recommends-funding-for-psoriasis-and-type-1-diabetes-drugs/
AbbVie ducks bolt-on trend and agrees Allergan mega-mergerUS drugmaker AbbVie has agreed to buy struggling Allergan in a $63 billion deal that continues a slew Share XAbbVie ducks bolt-on trend and agrees Allergan mega-mergerhttps://pharmaphorum.com/news/abbvie-ducks-bolt-on-trend-and-agrees-allergan-mega-merger/
AZ prepares for showdown with AbbVie/J&J as Calquence shines in CLLAstraZeneca has announced data showing its cancer drug Calquence outperformed standard care in chronic lymphocytic leukaemia – reducing Share XAZ prepares for showdown with AbbVie/J&J as Calquence shines in CLLhttps://pharmaphorum.com/news/az-prepares-for-showdown-with-abbvie-jj-as-calquence-shines-in-cll/
AbbVie makes case for Humira follow-on upadacitinib at EULARThe summer medical conference season is well and truly upon us and much of the focus this week Share XAbbVie makes case for Humira follow-on upadacitinib at EULARhttps://pharmaphorum.com/news/abbvie-makes-case-for-humira-follow-on-upadacitinib-at-eular/
AbbVie pulls phase 3 ADC trials in glioblastoma after survival missAbbVie is the latest company to have an investigational drug for glioblastoma multiforme (GBM) – an aggressive form Share XAbbVie pulls phase 3 ADC trials in glioblastoma after survival misshttps://pharmaphorum.com/news/abbvie-pulls-phase-3-adc-trials-in-glioblastoma-after-survival-miss/
Roche and AbbVie’s Venclexta approved in CLLRoche and AbbVie’s Venclexta (venetoclax) has been approved by the FDA in combination with Roche’s Gazyva (obinutuzumab) for Share XRoche and AbbVie’s Venclexta approved in CLLhttps://pharmaphorum.com/news/roche-and-abbvies-venclexta-approved-in-cll/
